Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616000123448
Ethics application status
Approved
Date submitted
22/01/2016
Date registered
3/02/2016
Date last updated
12/02/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
The role of oral bacteria on blood nitrite concentration following a beverage high in inorganic nitrate (beetroot juice)
Scientific title
The role of nitrate reductase bacteria on plasma nitrite concentration following an acute oral inorganic nitrate dose in healthy volunteers
Secondary ID [1] 288367 0
Nil known
Universal Trial Number (UTN)
U1111-1178-7106
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Apparently Healthy participants, looking at blood pressure 297362 0
Condition category
Condition code
Cardiovascular 297551 297551 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Participants will consume two 70mL bottles of beetroot juice containing a total of 8.4mmol of nitrate. (BEET IT shot, James White Drinks, Ipswich, UK).

The beetroot juice will be consumed as a one off, during the testing visit, in the presence of the investigator.
Intervention code [1] 293669 0
Treatment: Other
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 297106 0
Plasma nitrite concentration:
Three mL of blood will be drawn from the antecubital vein by a certified technician. Samples will be snap frozen with liquid nitrogen and stored at -70 degrees Celsius. 2 blood draws will be required, one before and one 2.5 hours after treatment.

Within 30 minutes of defrosting, all NO metabolite concentrations will be measured by chemiluminescence using Ionics/Sievers nitric oxide analyser.
Timepoint [1] 297106 0
Two and a half hours after beetroot juice consumption
Primary outcome [2] 297188 0
Oral Microbiome Profiling:

A tongue swab will be collected via the use of a sterile cotton swab will be rotated over the anterior dorsal tongue surface from left to right.

Clinical specimens will undergo routine microbiological analyses using a series of aerobic and anaerobic culture media. Bacteria from single colonies will be used for MALDI-TOF analysis to profile proteins within the bacteria and allow for identification of specific types of bacteria.
Timepoint [2] 297188 0
Specimen will be collected before supplementation as we hypothesise that the already established oral microbiome of an individual will affect the conversion of the supplemented nitrate (in the form of beetroot juice) to plasma nitrite.
Secondary outcome [1] 320032 0
Brachial Artery Blood Pressure: Blood pressure readings will be taken in accordance to the World Health Organisation’s STEP wise approach for measuring blood pressure with a stethoscope and sphygmanometer by a practiced technician. The participant will be asked to be seated for 15 minutes. 3 blood pressure measurements will be taken and the participant will rest 3 minutes in between each measurement. The second and third measurements will be averaged to obtain the participants blood pressure reading.
Timepoint [1] 320032 0
Two and a half hours after beetroot juice consumption

Eligibility
Key inclusion criteria
Male and Female
Age: 18-70 years
Non-Smoker (or not smoked for the last 3 months)
Resting SBP between 90 and 180mmHg
Resting DBP between 60 and 110mmHg
BMI under 30kg.m2
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Informed they have a dental cavity, dental surgery or oral disease in the last 3 months
Currently taking antibiotics
Currently taking Proton Pump Inhibitor medications ie. Omeprazole
Have been diagnosed with a Cardiovascular Disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The sample size for this project has been set at 75 participants.

We do not have preliminary data or a previous model to base this study on which makes sample size requirements difficult. This study is a pilot study that will provide effect size data to help in the design of a confirmatory study.

The sample size for this study has been chosen in consideration of the practical and financial limitations associated with the project. As a research group however we feel 75 subjects will likely be the maximum number we would like to recruit to inform future research funding applications, studies and generate an interesting publication.

We hope to obtain a heterogeneous population to help establish variance and confirm future confirmation studies.

Investigations in the human microbiome usually require many more subjects than 75 although it is difficult to get an accurate estimation for this as often they are actually characterising the microbiome. For example the NIH Human Microbiome Project to define normal bacterial makeup of the human body used data from 200 members of the Human Microbiome Project Consortium from nearly 80 universities and scientific institutions to report on 5 years of research. In addition the Human Oral Microbiome Database includes 1691 taxa in 13 phyla.

It is in keeping all of these factors in mind, that we believe 75 participants is an appropriate sample size for this pilot study.

Recruitment
Recruitment status
Withdrawn
Reason for early stopping/withdrawal
Lack of funding/staff/facilities
Date of first participant enrolment
Anticipated
6/03/2017
Actual
Date of last participant enrolment
Anticipated
10/12/2017
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
75
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 292717 0
University
Name [1] 292717 0
Victoria University
Country [1] 292717 0
Australia
Primary sponsor type
University
Name
Victoria University
Address
Ballarat Road, Footscray, Vic, 3011
Country
Australia
Secondary sponsor category [1] 291449 0
Commercial sector/Industry
Name [1] 291449 0
Bioscreen: Specialist Medical Testing Laboratory
Address [1] 291449 0
5 Little Hyde Street, Yarraville, Vic, 3013
Country [1] 291449 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 294207 0
Human Research Ethics, Victoria University
Ethics committee address [1] 294207 0
Ethics committee country [1] 294207 0
Australia
Date submitted for ethics approval [1] 294207 0
30/11/2015
Approval date [1] 294207 0
14/03/2017
Ethics approval number [1] 294207 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 62886 0
Prof Jason Allen
Address 62886 0
Victoria University
Footscray Park Campus
Ballarat Rd, Footscray VIC 3011
Country 62886 0
Australia
Phone 62886 0
+61 3 9919 4264
Fax 62886 0
Email 62886 0
[email protected]
Contact person for public queries
Name 62887 0
Jason Allen
Address 62887 0
Victoria University
Footscray Park Campus
Ballarat Rd, Footscray VIC 3011
Country 62887 0
Australia
Phone 62887 0
+61 3 9919 4264
Fax 62887 0
Email 62887 0
[email protected]
Contact person for scientific queries
Name 62888 0
Jason Allen
Address 62888 0
Victoria University
Footscray Park Campus
Ballarat Rd, Footscray VIC 3011
Country 62888 0
Australia
Phone 62888 0
+61 3 9919 4264
Fax 62888 0
Email 62888 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.